Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Everolimus (Certican) to prevent ESRD in ADPKD
2006-001485-16Phase 3Completed
- Sponsor
- Novartis
- Start
- Nov 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in autosomal dominant polycystic kidney disease (ADPKD) comparing Everolimus (Certican) with Placebo (2 arms). Primary endpoint: Change in total kidney volume at 24 months. Started Nov 2006; status: completed.
02
Drugs
everolimus
03
Conditions
autosomal dominant polycystic kidney disease (ADPKD)
Beyond the preview
Go deeper on 2006-001485-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-001485-16.